Impairments in left ventricular mitochondrial bioenergetics precede overt cardiac dysfunction and remodelling in Duchenne muscular dystrophy

Key Points Summary

‐98% of patients with Duchenne muscular dystrophy (DMD) develop cardiomyopathy, with 40% developing heart failure ‐While increased propensity for mitochondrial induction of cell death has been observed in left ventricle, it remains unknown whether this is linked to impaired mitochondrial respiratory control and elevated H₂O₂ emission prior to the onset of cardiomyopathy ‐Classic mouse models of DMD demonstrate hyper‐regeneration in skeletal muscle which may mask mitochondrial abnormalities. Using a model with less regenerative capacities that is more akin to DMD patients, we observed elevated left ventricular mitochondrial H₂O₂ and impaired oxidative phosphorylation in the absence of cardiac remodelling or overt cardiac dysfunction at 4 weeks ‐These impairments were associated with dysfunctions at Complex I, governance by ADP and creatine‐dependent phosphate shuttling which results in a less efficient response to energy demands ‐Mitochondria may be a therapeutic target for the treatment of cardiomyopathy in DMD

Abstract

In Duchenne muscular dystrophy (DMD), mitochondrial dysfunction is predicted as a response to numerous cellular stressors yet the degree and contribution of mitochondria to the onset of cardiomyopathy remains unknown. To resolve this uncertainty, we designed in vitro assessments of mitochondrial bioenergetics to model mitochondrial control parameters that influence cardiac function. Both left ventricular mitochondrial responsiveness to the central bioenergetic controller ADP as well as the ability of creatine to facilitate mitochondrial‐cytoplasmic phosphate shuttling were assessed. These measurements were performed in D2.B10‐DMD ^mdx/2J mice – a model that demonstrates skeletal muscle atrophy and weakness due to limited regenerative capacities and cardiomyopathy more akin to people with DMD than classic models. At 4 weeks of age, there was no evidence of cardiac remodelling or cardiac dysfunction despite impairments in ADP‐stimulated respiration and ADP‐ attenuation of H₂O₂ emission. These impairments were seen at both sub‐maximal and maximal ADP concentrations despite no reductions in mitochondrial content markers. The ability of creatine to enhance ADP's control of mitochondrial bioenergetics was also impaired, suggesting an impairment in mitochondrial creatine kinase‐dependent phosphate shuttling. Susceptibly to permeability transition pore opening and the subsequent activation of cell death pathways remained unchanged. Mitochondrial H₂O₂ emission was elevated despite no change in markers of irreversible oxidative damage, suggesting alternative redox signalling mechanisms should be explored. These findings demonstrate that selective mitochondrial dysfunction precedes the onset of overt cardiomyopathy in D2.mdx mice, suggesting that improving mitochondrial bioenergetics by restoring ADP, creatine‐dependent phosphate shuttling and Complex I should be considered for treating DMD patients.

This article is protected by copyright. All rights reserved

from Physiology via xlomafota13 on Inoreader http://bit.ly/2RbeTOy
via IFTTT